Research programme: antibody cancer therapeutics - Boehringer Ingelheim/Oxford BioTherapeutics

Drug Profile

Research programme: antibody cancer therapeutics - Boehringer Ingelheim/Oxford BioTherapeutics

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Oxford BioTherapeutics
  • Developer Boehringer Ingelheim; Oxford BioTherapeutics
  • Class Antibodies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for research development in Cancer in United Kingdom (Parenteral)
  • 18 Apr 2016 Boehringer Ingelheim exercises an option for exclusive development and commercialisation rights to second cancer antibody drug target
  • 14 Jan 2015 Boehringer Ingelheim exercises an option for exclusive development and commercialisation rights to first cancer antibody drug target
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top